SK Biopharmaceuticals Boosts U.S. Sales Push
SK Life Science, the U.S. subsidiary of SK Biopharmaceuticals, held its '2026 Plan of Action (POA)' meeting in Chicago, Illinois, from Sep. 29 to Oct. 1, local time.The meeting brought together sales personnel from the U.S. pharmaceutical and biotech industry to review sales performance and share fu
From September 29 to October 1 in Chicago, Illinois, SK Life Science, the U.S. subsidiary of SK Biopharmaceuticals, convened its 2026 Plan of Action (POA) meeting. More than 160 sales personnel from the U.S. pharmaceutical and biotech industry participated in the discussion to review sales performance and share future strategies.
The meeting, which followed the 2025 National Sales Meeting (NSM) theme of "We Will," aimed to implement the "One Team" strategy and foster proactive growth among team members. The focus was on accelerating cenobamate's growth momentum by analyzing first-half performance and market changes, while also expanding commercialization capabilities for new product introductions.
SK Life Science continues to enhance growth opportunities for its flagship product, cenobamate. The company is diversifying its formulations, considering an oral suspension and expanding patient populations to include pediatric and adolescent patients, as well as primary generalized tonic-clonic (PGTC) seizures. SK Biopharmaceuticals President Lee Dong-hoon emphasized that the U.S. sales organization is the most potent execution foundation driving cenobamate's growth.
He stated that both headquarters and field teams are determined to move faster towards a multi-product era, demonstrating tangible results.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
